Patent 11860161 was granted and assigned to Seattle Children's on January, 2024 by the United States Patent and Trademark Office.
Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.